Lymphoma, Non-Hodgkin Clinical Trial
Official title:
Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies
Background:
- Researchers are working to make stem cell transplant procedures safer and more effective.
One complication of transplants is graft-versus-host disease (GVHD). This complication
happens when certain white blood cells from the donor attack the recipient's own body.
Researchers want to test a blood separator machine that may help remove more of the donor's
white blood cells before transplant. They will study donors and recipients during stem cell
transplant to see how well this process can prevent GVHD and other complications.
Objectives:
- To see if a new blood separator machine can improve outcomes of stem cell transplants.
Eligibility:
- Individuals between 10 and 75 years of age who are having a stem cell transplant for
leukemia or other blood-related cancers.
- Donors for the stem cell transplant.
Design:
- Recipients and donors will be screened with a physical exam and medical history.
- Donors will have two blood collection procedures. The first will collect only white
blood cells, and return the rest of the blood. After the first collection, participants
will have filgrastim injections to help their stem cells enter their blood. Then, they
will have a second blood collection for the stem cells.
- Recipients will have radiation and chemotherapy to prepare for the stem cell transplant.
They will then have the stem cell transplant with the donor cells that have been treated
with the blood separator machine.
- Recipients will be monitored closely after the procedure. They may receive some of their
donor's white blood cells if needed to fight serious infections.
- Recipients will have the regular standard of care after their transplant. Blood samples
will be taken and any side effects will be monitored and treated.
Peripheral blood stem cell transplant research carried out by the NHLBI BMT Unit focus on
transplant techniques designed to decrease graft versus host disease (GVHD), increase the
graft-versus-leukemia (GVL) effect and reduce the risk of post-transplant graft rejection.
Through incremental transplant clinical trials we have shown that by controlling the stem
cell (CD34+ cell) and T lymphocyte (CD3+ cell) dose, severe GVHD can be reduced whilst
beneficial GVL effects can be preserved. We found that T cell depleted transplants using the
Nexell/Baxter Isolex 300i system and subsequently, the Miltenyi CliniMACS[registered] CD34+
system to obtain high CD34+ doses depleted of lymphocytes were safe to administer and
associated with less severe acute GVHD and promising response rates and overall survival. Our
previous trials have helped us to create the transplant environment (significant
lymphodepletion and minimal post transplant immunosuppression) that make for an ideal
platform for adoptive cellular immunotherapy. Adoptive cell transfer is the passive transfer
of immune cells, into a new recipient host with the goal of transferring the immunologic
functionality and characteristics into the new host.
This protocol is designed to evaluate the safety and efficacy of the Miltenyi
CliniMACS[registered] CD 34 selection system in HLA-matched sibling allogeneic peripheral
blood stem cell transplant. The manipulation of the graft is the primary research
intervention, subject to IDE# 15632, and all other aspects of clinical management on this
protocol are standard care. The target CD34+ dose range will be >3 x 10(6)/kg and the target
CD3+ dose range will be 5 x 10(4)/kg to 1 x 10(6)/kg. Once we demonstrate adequacy of this
platform for engraftment and absence of significant GVHD in ten consecutive recipients, we
will seek IRB permission to proceed with planned adoptive cellular therapies.
The protocol will accrue up to 96 transplant recipients aged 10-80 with a hematological
malignancy and their HLA-matched sibling donors, in whom allogeneic stem cell transplantation
from an HLA-matched sibling would be routinely indicated. Diagnostic categories will include
acute and chronic leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma and
myeloproliferative syndromes.
Subjects will receive a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg
total), fludarabine (125 mg/m(2) total) and total body irradiation (1200 cGy with lung
shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+
progenitors using the Miltenyi CliniMACS[registered] system. Older subjects will receive a
lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
The overall objective is to assess the feasibility of using this system as a platform for
cellular immunotherapy initiatives. The primary study endpoint will be overall survival at
day +200. Stopping criteria for safety will monitor non-relapse mortality at day +200 and
late disease free survival at 2 years. Secondary endpoints will be standard transplant
outcome variables such as non-hematologic toxicity, incidence and severity of acute and
chronic GVHD and relapse of disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03484702 -
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Completed |
NCT06190457 -
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
|
||
Completed |
NCT02369016 -
Phase III Copanlisib in Rituximab-refractory iNHL
|
Phase 3 | |
Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
Withdrawn |
NCT00319332 -
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
|
Phase 3 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Completed |
NCT00141297 -
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT00322842 -
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
|
Phase 2 | |
Completed |
NCT02509039 -
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
|
Phase 1 | |
Completed |
NCT00268203 -
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT01573000 -
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
Completed |
NCT03289182 -
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
|